skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
F16-IL2 Fusion Protein (Code C91395)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: F16-IL2 Fusion Protein

Definition: An immunocytokine of the human monoclonal antibody fragment F16 (scFv) against the extra-domain A1 of tenascin-C fused, via a short 5-amino acid linker, to a recombinant form of the human cytokine interleukin-2 (IL-2) with potential immunostimulating and antineoplastic activities. The monoclonal antibody portion of the F16-IL2 fusion protein binds to tumor cells expressing the tumor associated antigen (TAA) tenascin-C. In turn, the IL-2 moiety of the fusion protein stimulates natural killer (NK) cells, macrophages and neutrophils and induces T-cell antitumor cellular immune responses thereby selectively killing tenascin-C-expressing tumor cells. In addition, F16-IL2 may potentiate the cytotoxicity of other chemotherapeutic agents. Tenascin-C, a glycoprotein of the extracellular matrix, is expressed in many cancer cell types.

Label: F16-IL2 Fusion Protein

NCI Thesaurus Code: C91395 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL421592  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
F16-IL2 Fusion Protein

External Source Codes: 
PDQ Closed Trial Search ID 674718
PDQ Open Trial Search ID 674718 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C91395
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom